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This retrospective cohort study examined the
clinical significance of isolated Staphylococcus
aureus central venous catheter (CVC) tip cultures
(i.e., positive tip cultures without concomitant
positive blood cultures). Subsequent S. aureus
bacteraemia was found in nine (12%) of 77
patients at a median time of 4 days after CVC
removal. A high co-morbidity score and no
effective antibiotic treatment within 48 h of CVC
removal were independent risk-factors for septic
complications following multivariate analysis. A
matched case-control study that compared the
above cohort with patients with CVC tip cultures
negative for S. aureus supported the significance
of these findings.
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Few data exist concerning the clinical signifi-
cance of central venous catheter (CVC) tip
cultures that are positive for Staphylococus aureus
in patients who have no blood cultures collected
around the time of CVC removal, or whose
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concomitant blood cultures do not grow S.
aureus (i.e., isolated CVC tip cultures) [1]. The
present report describes a retrospective cohort
study of all adult patients with isolated S. aureus
CVC tip cultures at two tertiary care medical
centres between January 1999 and December
2004.
Cases were defined as patients who: (i) had a
distal CVC tip culture that grew ‡ 15 S. aureus
colonies by the roll-plate technique, and (ii) either
did not have blood cultures taken, or had negat-
ive blood cultures taken between 2 days before
and 1 day after CVC removal (concomitant blood
cultures) [2]. A subsequent septic complication
was defined as isolation of S. aureus with an
antibiotic susceptibility pattern identical to the
CVC tip isolate from a normally sterile site
between 3 days and 12 weeks after CVC removal.
Additionally, a matched, nested, 1:1 case-control
study was performed to compare the S. aureus
complication rate in the cases with that in a
similar patient cohort with CVC tip cultures
negative for S. aureus. Control patients were
selected randomly and matched by age, Charlson
index, and stay in a surgical or medical intensive
care unit. The Charlson index reflects the sum of a
patient’s weighted co-morbidities and predicts
mortality [3–5]. Therapy was considered appro-
priate if treatment with at least one antibiotic to
which susceptibility was documented was started
within 24 h before and 48 h after CVC removal
(adapted from [6]). S. aureus processing was
performed according to CLSI guidelines [7,8].
The study was approved by the institutional
review boards of the hospitals concerned.
Septic complication was the outcome of inter-
est. Bivariate analyses were conducted by Pear-
son’s chi-square test, Fisher’s exact test or the
Mann–Whitney U-test, as appropriate, to identify
factors associated with the outcome (p < 0.05).
Variables with p < 0.2 were entered into a back-
ward stepwise non-conditional logistic regression
analysis to identify independent risk-factors. In
the case-control study, McNemar’s test and the
Wilcoxon signed-rank test were used to compare
categorical and continuous variables, respec-
tively; the log-rank test was used to compare the
rates of septic complications.
Of 101 isolated S. aureus CVC tip cultures, 24
were excluded for the following reasons: follow-
up of £ 12 weeks or incomplete medical records
(n = 11); invasive S. aureus infection in £ 12 weeks
(n = 3); death within 48 h of CVC removal (n = 3);
CVC tip with multiple organisms (n = 3); concur-
rent non-bacteraemic S. aureus infection (n = 2);
and S. aureus bacteraemia 24–48 h after CVC
removal (n = 2). The final cohort comprised 77
consecutive patients with a mean age of 59 years;
nine (12%) of 77 patients developed a subsequent
S. aureus-related complication, all of which were
bacteraemia. One patient died from S. aureus-
related septic shock.
Table 1 shows the results of the bivariate
analyses. A high Charlson index, chronic
obstructive pulmonary disease (COPD), and no
effective antibiotic therapy received within 48 h
of CVC removal, were all factors associated with
septic complications. Only two (3%) of 59 patients
who had received appropriate antibiotics within
48 h of CVC removal developed subsequent
bacteraemia, compared with seven (39%) of 18
patients who had not received appropriate anti-
biotics. The median duration of antibiotic treat-
ment in patients with no complication was
12 days.
Table 1. Risk-factors for Staphylococcus aureus-related sep-
tic complications among 77 patients with isolated S. aureus
central venous catheter tip cultures
Characteristic
Cases with
complicationsa
(n = 9)
Cases without
complicationsa
(n = 68) OR (95% CI) p
Mean age ± SD (years) 55 ± 24 59 ± 17 > 0.2
Male gender 7 (78) 44 (65) 1.91 (0.37–9.92) > 0.2
Stay in ICU 3 (33) 26 (38) 0.81 (0.19–3.51) > 0.2
Co-morbid conditions
Charlson score ‡ 5 5 (56) 10 (15) 7.25 (1.66–31.71) 0.01
Diabetes mellitus 5 (56) 17 (25) 3.75 (0.90–15.59) 0.11
COPD 5 (56) 10 (15) 7.25 (1.66–31.71) 0.01
Haemodialysis
dependency
0 (0) 3 (4) – > 0.2
Current malignancy 3 (33) 20 (29) 1.20 (0.27–5.28) > 0.2
Intravascular deviceb 2 (22) 12 (18) 1.33 (0.25–7.23) > 0.2
Orthopaedic device 0 (0) 10 (15) – > 0.2
Previous surgeryc 4 (44) 34 (50) 0.80 (0.20–3.24) > 0.2
CVC exit site infection 3 (33) 28 (41) 0.71 (0.17–3.10) > 0.2
SIRSd 4 (44) 39 (57) 0.59 (0.15–2.41) > 0.2
Non-tunnelled CVCe 7 (78) 54 (79) 0.91 (0.17–4.86) > 0.2
Concomitant blood
cultures performed
4 (44) 40 (59) 0.56 (0.14–2.27) > 0.2
MRSA 6 (67) 41 (60) 1.32 (0.30–5.72) > 0.2
No effective antibiotics
by day 2
7 (78) 11 (16) 18.14 (3.32–99.16) < 0.001
28-day mortality rate 1 (11) 6 (9) 1.29 (0.14–12.15) > 0.2
ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CVC,
central venous catheter; SIRS, systemic inflammatory response syndrome; MRSA,
methicillin-resistant Staphylococcus aureus.
aTotal number (percentage) or mean ± SD.
bInferior vena cava filter (n = 5), pacemaker or implantable cardiac defibrillator
(n = 3), synthetic intravascular graft (n = 2), prosthetic heart valve (n = 2), coronary
artery stent (n = 1), transjugular intrahepatic portosystemic shunt (n = 1).
cWithin the previous 6 months.
dSee [17].
eOther: tunnelled CVCs (n = 7), totally implantable devices (n = 7), and peripher-
ally inserted central catheters (n = 2).
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Logistic regression analysis revealed two inde-
pendent risk-factors for septic complications,
namely a Charlson index ‡ 5 (adjusted OR 9.07;
95% CI 1.42–57.92; p 0.02) and no effective antibi-
otic therapy received within 48 h of CVC removal
(adjusted OR 21.23; 95% CI 3.20–140.77; p 0.002).
Table 2 shows the results of the case-control
study. Only two (2%) control patients, compared
with nine (12%) case patients, developed septic
complications (p 0.03); these occurred at a median
of 62 and 4 days, respectively, after CVC removal
(p 0.03).
S. aureus catheter tip cultures are accompanied
frequently by positive blood cultures [9,10], and
findings at the institutions in the present study, in
which 267 (73%) of 368 S. aureus CVC tip cultures
were associated with concurrent bacteraemia,
agree with this observation. However, the clinical
significance of isolated S. aureus CVC tip cultures
has not been defined [1]. To our knowledge, the
present study is the first to investigate specifically
the outcome of patients with this clinical entity.
Nine (12%) patients with isolated S. aureus CVC
tip cultures were identified who developed bac-
teraemia between 3 and 33 days after catheter
removal. A high Charlson index and a failure to
receive effective antibiotics within 48 h of CVC
removal were the only independent risk-factors
for subsequent septic complications. The latter
also remained the only independent predictor in
an analysis of a subgroup of 44 patients who had
negative concomitant blood cultures (data not
shown). This finding, together with the results of
the matched case-control study, supports the
conclusion that the subsequent bacteraemic epi-
sodes signify a genuine complication, rather than
merely non-detection of S. aureus bacteraemia at
the time of CVC removal or the existence of an
independent healthcare-related complication.
COPD has not been associated with S. aureus
bacteraemia in previous reports; its significance
in bivariate analysis may be an artefactual
finding caused by multiple testing. The majority
(57%) of non-tunnelled CVCs was inserted into
the subclavian vein. Catheter location and rate
of septic complications were not related (p
> 0.2). The pathogenic mechanisms responsible
for subsequent S. aureus septic complications are
unknown. The potential role of small, clinically
non-evident, intravascular thrombi, or low-grade
bacteraemia caused by mechanical manipulation
at the time of CVC removal, remain to be
determined [11].
There were limitations to the study. Blood and
CVC tip isolates were not available for molecular
typing [12,13], so their relatedness could not be
confirmed. Only 21% of the patients underwent
echocardiography; therefore, endocarditis may
have been under-diagnosed [14,15]. The study
was also limited by its retrospective design;
however, strict inclusion criteria were used to
minimise sampling, misclassification and surveil-
lance bias [16].
In summary, isolated S. aureus CVC tip cultures
were associated with a significant risk of septic
complications. If validated, the data would indi-
cate that patients with this clinical entity should
receive a course of anti-staphylococcal antibiotics,
the optimal duration of which remains to be
determined.
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Table 2. Comparison of patient characteristics in the
matched nested case-control study
Characteristic
Cases (%)
(n = 77)
Controls (%)
(n = 77) p
Mean age ± SD (years)a 59 ± 18 59 ± 15 > 0.2
Male gender 51 (66) 47 (61) > 0.2
Stay in ICUa 29 (38) 29 (38) > 0.2
Co-morbid conditions
Median Charlson
score (range)a
2 (0–11) 2 (0–10) > 0.2
Diabetes mellitus 22 (29) 16 (21) > 0.2
COPD 15 (20) 19 (25) > 0.2
Chronic liver disease 8 (10) 8 (10) > 0.2
Haemodialysis dependence 3 (4) 2 (3) > 0.2
Current malignancy 23 (30) 29 (38) > 0.2
Intravascular deviceb 14 (18) 12 (16) > 0.2
Orthopaedic device 10 (13) 3 (4) 0.15
CVC exit site infection 31 (40) 17 (22) 0.06
SIRS 43 (56) 40 (52) > 0.2
Non-tunnelled CVC 61 (79) 63 (82) > 0.2
Days of hospitalisation
after CVC tip culture
obtained (range)
9 (0–82) 14 (0–122) > 0.2
Complicating
Staphylococcus
aureus bacteraemiac
9 (12) 2 (2) 0.03
28-day mortality rate 7 (9) 11 (14) > 0.2
ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CVC,
central venous catheter; SIRS, systemic inflammatory response syndrome.
aThese variables were used in the matching process.
bInferior vena cava filter (n = 8), pacemaker or implantable cardiac defibrillator
(n = 7), synthetic intravascular graft (n = 5), prosthetic heart valve (n = 3), intra-
vascular stent (n = 2), transjugular intrahepatic portosystemic shunt (n = 1).
c£ 12 weeks.
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DNAmicroarray technology was used to evaluate
differential gene expression in a susceptible Kle-
bsiella pneumoniae isolate and a resistant clinical
derivative. Nineteen genes were up-regulated in
the resistant isolate when compared with the
susceptible isolate. An ABC transporter-related
gene, ycjV, was strongly over-expressed, suggest-
ing the existence of a novel active efflux mechan-
ism. Approximately half of the up-regulated
genes coded for ribosomal proteins, or proteins
involved in tRNA metabolism. Among 33 down-
regulated genes, almost one-third were related to
nitrogen metabolism. A possible role of fitness in
the development of antimicrobial resistance is
suggested.
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